Is TB-500 Legal in New York? How to Access It Legally
HealthRX.com
No federal document makes TB-500 clearly legal in New York
See the public record for TB-500
At a glance
- What it is / a synthetic 7-amino-acid fragment of thymosin beta-4 [1]
- FDA approval / none in the US, and no approved product found in Canada, Australia, the UK or several European countries [1]
- FDA lists / in none of the three categories for state-licensed pharmacies and physicians, and not on the outsourcing-facility list [2][3][4]
- FDA safety-risk page / nominated-but-withdrawn table, not active category 2 [7]
- HHS draft policy / TB-500 acetate injection; non-binding [5][6]
- Sport / prohibited at all times by WADA [8][9]
What TB-500 Is
TB-500 is a synthetic 7-amino-acid, N-acetylated fragment of thymosin beta-4 (residues 17 to 23, about 889 g/mol), not the full 43-amino-acid protein [1]. 'TB-500' is a common name, and FDA found several salts and derivatives sold under it [1]. Human trials of full-length thymosin beta-4 tested a different molecule [10][11].
Where It Stands With FDA
FDA's July 2026 review found no USP or National Formulary monograph for TB-500 and no FDA-approved drug containing it [1]. It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated 14 May 2026) and is not on FDA's list for outsourcing facilities, so the category 1 policy (generally no action against a compounder that meets the guidance conditions) does not cover it [2][3][4]. FDA found no pharmacy marketing a compounded TB-500 product [1].
On FDA's safety-risk page, TB-500 sits in the 'nominated but withdrawn' table, not the active category 2 table, and removal from category 2 was not a finding that it is safe [7].
The Pharmacy Compounding Advisory Committee voted in favor of listing it on 23 July 2026, against FDA staff's recommendation; TB-500 is not on the list [12][1]. HHS's draft policy (Federal Register document 2026-22192, filed 28 October 2026) covers TB-500 acetate by subcutaneous or intramuscular injection and says HHS 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with it when the policy's conditions are met; the notice says it 'does not establish any rights for any person and is not binding on HHS or the public' [5][6].
Does That Make It Legal in New York?
The federal position does not establish that TB-500 can be lawfully compounded or dispensed. New York's own pharmacy and medical practice rules apply separately from the federal position. Compounded drugs are not FDA-approved, and FDA does not review their safety, effectiveness or quality before they reach patients [5].
Questions worth asking
Sport
WADA names 'Thymosin-beta4 and its derivatives e.g. TB-500' in section S2.3 (growth factors and growth factor modulators), prohibited at all times in and out of competition; it is on the 2026 List in force since 1 January 2026 and stays on the 2027 List [8][9].
What Is Known About Safety
FDA found no study in which TB-500 was given to a person, and none of the three papers the nominator cited involved TB-500 in humans [1]. There is no approved dose; the nomination FDA reviewed proposed a 3 mg/mL lyophilized powder for injection, a proposed formulation rather than a recommended dose [1]. FDA's adverse-event database search through 26 March 2025 retrieved no TB-500 reports, and its food and supplement complaint system retrieved two cases about a blended TB-500 and BPC-157 product with no safety assessment [1]. FDA's stated concern for injectable TB-500 is immunogenicity, potentially amplified by peptide aggregation and impurities [1].
Frequently asked questions
Is TB-500 legal in New York?
Is TB-500 the same as thymosin beta-4?
Did the 2026 advisory vote make TB-500 legal?
Can athletes use TB-500?
References
Show all 12 referencesHide references
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- U.S. Food and Drug Administration.
- Bulk Drug Substances Used in Compounding of the FD&C Act | FDA.
- Official web page.
- Official web page.
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks | FDA.
- World Anti-Doping Agency.
- World Anti-Doping Agency.
- Wang X, Liu L, Qi L, Lei C, Li P, Wang Y, et al. A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. J Cell Mol Med. 2021;25(17):8222-8228.
- Sosne G, Ousler GW. Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE™) model. Clin Ophthalmol. 2015;9:877-84.
- U.S. Food and Drug Administration.